CAPR (US) share price forecast & AI signal — Capricor Therapeutics, Inc
Week of 2026-10-30 · Healthcare
Exact confidence, 1-week / 1-month / 3-month breakdown, plain-English AI write-up, bull-vs-bear debate, support & resistance.
Get 5 free tokens — no card Already a member? Open the full analysisWhat the model sees in CAPR
Capricor Therapeutics, Inc is a Healthcare stock listed on the US. For the week of 2026-10-30 the ACE machine-learning model rates it a SELL with moderate confidence, based on technical indicators and the stock's own historical patterns across three time horizons. The direction is updated every model run.
About Capricor Therapeutics, Inc
Capricor Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of transformative cell and exosome-based therapeutics for treating duchenne muscular dystrophy (DMD) and other diseases with unmet medical needs in the United States. Its lead product candidate is the Deramiocel, an allogeneic cardiosphere-derived cells, which is in phase 3 clinical trial for the treatment of DMD. The company also develops Exosome protein-based vaccine, which is in preclinical trial to treat SARS-CoV-2; StealthX Exosome Platform, and exosome platform program consists of engineered exosomes for vaccine and therapeutic development and is in preclinical trial. In addition, it...
Recent closes
| Date | Close |
|---|---|
| 2026-11-06 | $9.00 |
| 2026-11-05 | $8.60 |
| 2026-11-04 | $8.92 |
| 2026-11-03 | $8.24 |
| 2026-11-02 | $7.24 |
| 2026-10-30 | $6.38 |
| 2026-10-29 | $6.63 |
CAPR FAQ
Is Capricor Therapeutics, Inc (CAPR) a buy or sell this week?
The ACE Stock Bots machine-learning model rates CAPR a SELL for the week of 2026-10-30 with moderate confidence. The exact confidence and the 1-week, 1-month and 3-month breakdown are free with a signup (5 analysis tokens, no card).
What is the AI share price forecast for CAPR?
Every week the model scores CAPR across three horizons using technical indicators and the stock's own historical patterns. An AI then writes a plain-English summary with support and resistance levels, and a bull analyst and a bear analyst argue the case.
Is this financial advice?
No. ACE Stock Bots provides general information generated by software. It does not consider your objectives, financial situation or needs. Read the disclaimer and consider licensed advice before acting.
Other Healthcare stocks on the US
This week's top US picks · All US stocks
Signals are generated by software for general information only and are not a recommendation to buy or sell. See the disclaimer.